Comparative analysis of a new IHC Assay for PD-L1 in NSCLC

Poster presented on ECP 2022 in Basel by NordiQC

Lung cancer is one of the leading causes of cancer-related mortalities
globally and especially the United States.1 The level of Program Death
Ligand-1 (PD-L1) IHC expression is used to select patients with nonsmall
cell lung carcinoma (NSCLC) for immunotherapy with anti-PD1
drugs such as pembrolizumab.2 PD-L1 protein expression is determined
by the tumor proportion score (TPS), where a TPS score > 1% is eligible
for treatment.3-4 Since patient stratification for anti-PD1 drugs is based on
IHC alone, our purpose is to determine the overall agreement between
the widely applied and well-characterized PD-L1 IHC 22C3 pharmDx and
a newly developed PD-L1 IHC Assay (clone RM320) in NSCLC.